Chris Walsh is General Counsel of Denali Therapeutics. As a strategic partner to Denali’s management team and Board, Chris leads the company’s legal function, overseeing the legal strategy across corporate governance, public-company securities and disclosures, collaborations and contracts, intellectual property, commercial readiness, employment, and litigation, in support of Denali’s mission.
Before joining Denali, Chris held positions of increasing responsibility at Genentech, where he guided intellectual property strategy across multiple therapeutic programs. Earlier in his career, he practiced patent law at Sterne, Kessler, Goldstein & Fox. Chris holds a Ph.D. in Organic Chemistry from the Illinois Institute of Technology and received his J.D. from The George Washington University Law School.